Stockscreener 앱 받기
1.04
2.97%
0.03
시간 외 거래:
1.05
0.01
+0.96%
Abvc Biopharma Inc 주식(ABVC)의 최신 뉴스
ABVC Biopharma Inc (ABVC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ABVC Biopharma Inc (ABVC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ABVC Biopharma Inc (ABVC) Cash Flow - TradingKey
ABVC Biopharma Inc (ABVC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ABVC Biopharma Inc (ABVC) Institutional Confidence - TradingKey
ABVC Biopharma Inc (ABVC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ABVC Biopharma Inc (ABVC) Balance Sheet - TradingKey
ABVC|ABVC Biopharma Inc|Price:1.030|Chg%:-0.120 - TradingKey
ABVC Biopharma Inc (ABVC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ABVC Biopharma Inc (ABVC) Valuation: PE, PB & Fair Value Analysis - TradingKey
ABVC Biopharma Inc (ABVC) Income Statement - TradingKey
ABVC Biopharma Inc (ABVC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ABVC BioPharma, Inc. Revenue Breakdown – NASDAQ:ABVC - TradingView
ABVC|ABVC Biopharma Inc|Price:1.150|Chg%:-0.050 - TradingKey
ABVC BioPharma Inc. (ABVC) Gains 3.3% as Shares Test Key ResistanceGEX Level - dars.gov.et
ABVC BioPharma Edges Lower, Trading Near Key Support at $1.27Volume Rate Change - dars.gov.et
MSN Money - MSN
ABVC BioPharma (ABVC) Rallies Over 6%, Testing Key Resistance at $2.12Volume Oscillator - dars.gov.et
ABVC BioPharma (ABVC) replaces auditor and reiterates going-concern language - Stock Titan
Price to sales forward of ABVC BioPharma, Inc. – NASDAQ:ABVC - TradingView
Enterprise value to EBITDA forward of ABVC BioPharma, Inc. – NASDAQ:ABVC - TradingView
Price to book forward of ABVC BioPharma, Inc. – NASDAQ:ABVC - TradingView
ABVC Should I Buy - Intellectia AI
ABVC BioPharma, Inc. Actuals & Estimates (NASDAQ:ABVC) - TradingView
ABVC Q1 2025 Earnings: EPS of -0.06 Reflects Ongoing R&D Investment; Stock Gains 2.82%Earnings Yield Spread - dars.gov.et
ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders - 富途牛牛
ABVC BioPharma to Spin Off BioKey Subsidiary via Dividend Distribution to Shareholders - MEXC
ABVC Q1 2025 Earnings: Loss Per Share of -$0.06 as Clinical Pipeline ProgressesBook Value Growth - dars.gov.et
ABVC Biopharma Inc (ABVC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ABVC BioPharma Inc. (ABVC) Surges 7.39% — Testing Key Resistance at $1.34Relative Volume - newsline.com
ABVC Q1 2025 Earnings: Net Loss of -$0.06 Per Share Reflects Pre‑Revenue Development Stage; Stock Declines 9.2% - newsline.com
ABVC BioPharma Inc. (ABVC) Edges Higher as Shares Test Resistance Near $1.41Ichimoku Kumo Break - newsline.com
ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Narrowing Losses Amid Clinical ProgressLow Estimate Range - dars.gov.et
ABVC Q1 2025 Earnings: No Revenue Reported, EPS Loss of -$0.06 Amid Ongoing R&D Focus - DonanımHaber
ABVC BioPharma Slips 7.6%: Support at $1.26 in Focus After Volatile SessionSeasonality Effect - newsline.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ABVC Q1 2025 Earnings: Narrowing Losses as Pipeline Progress Drives Stock SurgeFull Year Guidance - dars.gov.et
ABVC PE Ratio & Valuation, Is ABVC Overvalued - Intellectia AI
ABVC Q1 2025 Earnings: Pre‑Revenue Biotech Reports Net Loss as Pipeline Development Continues - newsline.com
ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Modest Loss Reported Amid Ongoing Clinical DevelopmentEarnings Growth Forecast - dars.gov.et
ABVC BioPharma Creeps Higher, Testing Resistance at $1.48Bullish Percent Index - The Legal Advocate
ABVC BioPharma Consolidates at $1.39 as Support and Resistance Levels NarrowPCR Divergence - The Legal Advocate
ABVC BioPharma Surges 13%: Key Levels and Potential ScenariosShort Term Trading Ideas - thelegaladvocate.com
ABVC BioPharma Inc. (ABVC) Surges 9.65% in Active Trading as Biotech Investor Sentiment ImprovesMcClellan Summation - The Legal Advocate
ABVC - Finviz
ABVC BioPharma Inc. (ABVC) Edges Higher After Recent Pullback, Testing Key Resistance LevelIV Expansion Alert - Newser
1.84%
0.91%
자본화:
|
볼륨(24시간):